February 16, 2022
A Novel, High-Throughput Platform to Characterize Novel IBD Therapeutics
Tumor Necrosis Factor Alpha (TNF-a) is a potent cytokine that is over-expressed by cells during chronic intestinal inflammation. Furthermore, TNF-a represents the most validated clinical target for ulcerative colitis (UC) and inflammatory bowel diseases (IBD) with multiple emerging neutralizing/inflammation-reducing therapeutics targeting this cytokine for inactivation. TNF-a activation of intestinal epithelia can disrupt the intestinal barrier via mechanisms including that activation of the inflammatory master regulators, including NFkB-induced IL-8 production and secretion, as well as having direct effects on tight junction integrity and cellular apoptosis.
August 5, 2021
The Power Of RepliGut® In Vitro Intestinal Stem Cell Models
Both current in vitro and in vivo models used in the development of candidate therapies for the treatment of intestinal diseases have severe limitations. RepliGut®, an in vitro human intestinal epithelial stem cell model, addresses many of these issues and has significant potential to reduce the time and cost of drug development. This model may even help to identify optimal therapies for individual patients.
April 12, 2021
Developing A Robust In Vitro Intestinal Model for Preclinical Candidate Screening of GI Toxicity
Gastrointestinal (GI) issues are common side effects of many drugs. Anticipating such side effects before clinical trials is limited by a lack of effective models for evaluating preclinical candidates for their potential to cause diarrhea, nausea, and other gut-related side effects. With its RepliGut® in vitro human intestinal model, Altis Biosystems is developing a system that could help pharma companies identify GI toxicity issues early in the drug development process.
March 11, 2021
Accurately Recapitulating Environmental Niches in In Vitro Models of the Intestine
Advanced microphysiological systems can replicate aspects of intestinal complexity, such as epithelium self-renewal by stem cells in in vitro crypts or the interactions of microbes and intestinal epithelium mediated by a mucus layer. Availability of such models is key to progress in compound screening, disease modeling, and microbiome research.
February 16, 2021
Recapitulating the Multifaceted Inflammatory Environment of the Intestine In Vitro
Intestinal inflammatory diseases are highly complex, which has thus far prevented development of an effective in vitro disease model. With access to a donor-derived cell biobank and the ability to recapitulate region-specific environments of the intestine, Altis Biosystems is working toward the development of an in vitro RepliGut® model to accurately recapitulate the complex intestinal inflammatory microenvironments.